Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United KingdomIPO:
23 May 2019Next earnings report:
01 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 29 Oct 2024 21:31:38 GMTDividend
Analysts recommendations
Institutional Ownership
BCYC Latest News
Bicycle Therapeutics (BCYC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
BARCELONA--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updated Phase 1/2 clinical results for Bicycle Toxin Conjugate (BTC®) zelenectide pevedotin (formerly BT8009) in metastatic urothelial cancer (mUC); BTC molecule BT5528 in advanced solid tumors, such as mUC and ovarian; and Bicycle Tumor-Targeted Immune Cell Agonist.
RBC Capital initiated coverage on Bicycle Therapeutics PLC BCYC, noting an advantage in oncology and beyond.
Bicycle Therapeutics (BCYC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The average of price targets set by Wall Street analysts indicates a potential upside of 88.9% in Bicycle Therapeutics (BCYC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Twist Bioscience (TWST) have performed compared to their sector so far this year.
Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
Bicycle Therapeutics (BCYC) gains 10% upon entering a PIPE financing agreement with multiple institutional investors, which is expected to generate gross proceeds of $555 million.
The consensus price target hints at an 85.5% upside potential for Bicycle Therapeutics (BCYC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that emerging Phase 1/2 clinical pharmacokinetic (PK) and safety data for Bicycle Toxin Conjugates® (BTC® molecules) BT8009 and BT5528 demonstrating differentiated safety and tolerability profiles will be presented at the 2024 American Society for.
- 1(current)
What type of business is Bicycle Therapeutics?
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
What sector is Bicycle Therapeutics in?
Bicycle Therapeutics is in the Healthcare sector
What industry is Bicycle Therapeutics in?
Bicycle Therapeutics is in the Biotechnology industry
What country is Bicycle Therapeutics from?
Bicycle Therapeutics is headquartered in United Kingdom
When did Bicycle Therapeutics go public?
Bicycle Therapeutics initial public offering (IPO) was on 23 May 2019
What is Bicycle Therapeutics website?
https://www.bicycletherapeutics.com
Is Bicycle Therapeutics in the S&P 500?
No, Bicycle Therapeutics is not included in the S&P 500 index
Is Bicycle Therapeutics in the NASDAQ 100?
No, Bicycle Therapeutics is not included in the NASDAQ 100 index
Is Bicycle Therapeutics in the Dow Jones?
No, Bicycle Therapeutics is not included in the Dow Jones index
When was Bicycle Therapeutics the previous earnings report?
No data
When does Bicycle Therapeutics earnings report?
The next expected earnings date for Bicycle Therapeutics is 01 November 2024